Pharmasset - Tapping Both IFN and IFN-Free Opportunities
Bristol-Myers announced topline PhII data of its once daily NS5A inhibitor (BMS-790052) +Peg-IFN/RBV. Efficacy data of BMS-790052 raises the probability of success of the ongoing trial of PSI-7977 + BMS-790052 (PhIIb, Nucleotide + NS5A inhibitor) - Once daily w/o IFN. PSI-7977+ Peg-IFN/RBV have shown advantage over the approved drugs and other drugs in the pipeline, besides promising of IFN-free combinations. For more details, please read our report released on 21th September, 2011 on VRUS titled “Tapping Both IFN and IFN-Free Opportunities”.
COMPANIES MENTIONED
Pharmasset
Pharmasset
More Publications
PHARMASSET - "IFN-free Oral Option" for HCV- Sharing the Big Pie!
US$ 140.00
November 2011
9 pages
PHARMASSET - 'IFN-Free Oral Option' for HCV - Not a Virgin Territory Anymore!
US$ 90.00
October 2011
4 pages
Hepatitis C: Battlefield at AASLD ‘11 - Next Wave: IFN-Free Drugs with Safety and Dosing Advantage
US$ 2,000.00
October 2011
13 pages
VERTEX PHARMA - IFN-free Oral HCV Treatment – Vertex Not Out of the Race Yet!
US$ 140.00
February 2012
12 pages
